<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39338946</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>24</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2076-0817</ISSN><JournalIssue CitedMedium="Print"><Volume>13</Volume><Issue>9</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>02</Day></PubDate></JournalIssue><Title>Pathogens (Basel, Switzerland)</Title><ISOAbbreviation>Pathogens</ISOAbbreviation></Journal><ArticleTitle>Influenza B Virus Vaccine Innovation through Computational Design.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">755</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/pathogens13090755</ELocationID><Abstract><AbstractText>As respiratory pathogens, influenza B viruses (IBVs) cause a significant socioeconomic burden each year. Vaccine and antiviral development for influenza viruses has historically viewed IBVs as a secondary concern to influenza A viruses (IAVs) due to their lack of animal reservoirs compared to IAVs. However, prior to the global spread of SARS-CoV-2, the seasonal epidemics caused by IBVs were becoming less predictable and inducing more severe disease, especially in high-risk populations. Globally, researchers have begun to recognize the need for improved prevention strategies for IBVs as a primary concern. This review discusses what is known about IBV evolutionary patterns and the effect of the spread of SARS-CoV-2 on these patterns. We also analyze recent advancements in the development of novel vaccines tested against IBVs, highlighting the promise of computational vaccine design strategies when used to target both IBVs and IAVs and explain why these novel strategies can be employed to improve the effectiveness of IBV vaccines.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pekarek</LastName><ForeName>Matthew J</ForeName><Initials>MJ</Initials><Identifier Source="ORCID">0000-0003-3214-4220</Identifier><AffiliationInfo><Affiliation>Nebraska Center for Virology, School of Biological Sciences, University of Nebraska-Lincoln, Lincoln, NE 68583, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weaver</LastName><ForeName>Eric A</ForeName><Initials>EA</Initials><Identifier Source="ORCID">0000-0002-5029-0662</Identifier><AffiliationInfo><Affiliation>Nebraska Center for Virology, School of Biological Sciences, University of Nebraska-Lincoln, Lincoln, NE 68583, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AI147109</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>1R01AI147109-04A1</GrantID><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Pathogens</MedlineTA><NlmUniqueID>101596317</NlmUniqueID><ISSNLinking>2076-0817</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">computational design</Keyword><Keyword MajorTopicYN="N">immunogen design</Keyword><Keyword MajorTopicYN="N">influenza B viruses</Keyword><Keyword MajorTopicYN="N">surveillance</Keyword><Keyword MajorTopicYN="N">vaccines</Keyword><Keyword MajorTopicYN="N">viral evolution</Keyword></KeywordList><CoiStatement>The authors hereby declare that the research was conducted without any commercial or financial relationships that could constitute potential conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>8</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>1</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39338946</ArticleId><ArticleId IdType="pmc">PMC11434669</ArticleId><ArticleId IdType="doi">10.3390/pathogens13090755</ArticleId><ArticleId IdType="pii">pathogens13090755</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Cassini A., Colzani E., Pini A., Mangen M.J., Plass D., McDonald S.A., Maringhini G., van Lier A., Haagsma J.A., Havelaar A.H., et al. Impact of infectious diseases on population health using incidence-based disability-adjusted life years (DALYs): Results from the Burden of Communicable Diseases in Europe study, European Union and European Economic Area countries, 2009 to 2013. Euro Surveill. 2018;23:17-00454. doi: 10.2807/1560-7917.ES.2018.23.16.17-00454.</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.ES.2018.23.16.17-00454</ArticleId><ArticleId IdType="pmc">PMC5915974</ArticleId><ArticleId IdType="pubmed">29692315</ArticleId></ArticleIdList></Reference><Reference><Citation>Leuba S.I., Yaesoubi R., Antillon M., Cohen T., Zimmer C. Tracking and predicting U.S. influenza activity with a real-time surveillance network. PLoS Comput. Biol. 2020;16:e1008180. doi: 10.1371/journal.pcbi.1008180.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pcbi.1008180</ArticleId><ArticleId IdType="pmc">PMC7707518</ArticleId><ArticleId IdType="pubmed">33137088</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO  Influenza (Seasonal)  [(accessed on 1 September 2023)].  Available online:  https://www.who.int/en/news-room/fact-sheets/detail/influenza-(seasonal)</Citation></Reference><Reference><Citation>Tokars J.I., Olsen S.J., Reed C. Seasonal Incidence of Symptomatic Influenza in the United States. Clin. Infect. Dis. 2018;66:1511–1518. doi: 10.1093/cid/cix1060.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/cix1060</ArticleId><ArticleId IdType="pmc">PMC5934309</ArticleId><ArticleId IdType="pubmed">29206909</ArticleId></ArticleIdList></Reference><Reference><Citation>Treanor J.J., El Sahly H., King J., Graham I., Izikson R., Kohberger R., Patriarca P., Cox M. Protective efficacy of a trivalent recombinant hemagglutinin protein vaccine (FluBlok®) against influenza in healthy adults: A randomized, placebo-controlled trial. Vaccine. 2011;29:7733–7739. doi: 10.1016/j.vaccine.2011.07.128.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2011.07.128</ArticleId><ArticleId IdType="pubmed">21835220</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei C.J., Crank M.C., Shiver J., Graham B.S., Mascola J.R., Nabel G.J. Next-generation influenza vaccines: Opportunities and challenges. Nat. Rev. Drug Discov. 2020;19:239–252. doi: 10.1038/s41573-019-0056-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41573-019-0056-x</ArticleId><ArticleId IdType="pmc">PMC7223957</ArticleId><ArticleId IdType="pubmed">32060419</ArticleId></ArticleIdList></Reference><Reference><Citation>Corder B.N., Bullard B.L., Poland G.A., Weaver E.A. A Decade in Review: A Systematic Review of Universal Influenza Vaccines in Clinical Trials during the 2010 Decade. Viruses. 2020;12:1186. doi: 10.3390/v12101186.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v12101186</ArticleId><ArticleId IdType="pmc">PMC7589362</ArticleId><ArticleId IdType="pubmed">33092070</ArticleId></ArticleIdList></Reference><Reference><Citation>Bullard B.L., Weaver E.A. Strategies Targeting Hemagglutinin as a Universal Influenza Vaccine. Vaccines. 2021;9:257. doi: 10.3390/vaccines9030257.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines9030257</ArticleId><ArticleId IdType="pmc">PMC7998911</ArticleId><ArticleId IdType="pubmed">33805749</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsybalova L.M., Stepanova L.A., Ramsay E.S., Vasin A.V. Influenza B: Prospects for the Development of Cross-Protective Vaccines. Viruses. 2022;14:1323. doi: 10.3390/v14061323.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v14061323</ArticleId><ArticleId IdType="pmc">PMC9228933</ArticleId><ArticleId IdType="pubmed">35746794</ArticleId></ArticleIdList></Reference><Reference><Citation>Lew W., Chen X., Kim C.U. Discovery and development of GS 4104 (oseltamivir): An orally active influenza neuraminidase inhibitor. Curr. Med. Chem. 2000;7:663–672. doi: 10.2174/0929867003374886.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/0929867003374886</ArticleId><ArticleId IdType="pubmed">10702632</ArticleId></ArticleIdList></Reference><Reference><Citation>Burnham A.J., Baranovich T., Govorkova E.A. Neuraminidase inhibitors for influenza B virus infection: Efficacy and resistance. Antiviral Res. 2013;100:520–534. doi: 10.1016/j.antiviral.2013.08.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2013.08.023</ArticleId><ArticleId IdType="pmc">PMC3850058</ArticleId><ArticleId IdType="pubmed">24013000</ArticleId></ArticleIdList></Reference><Reference><Citation>Koszalka P., Subbarao K., Baz M. Preclinical and clinical developments for combination treatment of influenza. PLoS Pathog. 2022;18:e1010481. doi: 10.1371/journal.ppat.1010481.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1010481</ArticleId><ArticleId IdType="pmc">PMC9098076</ArticleId><ArticleId IdType="pubmed">35551301</ArticleId></ArticleIdList></Reference><Reference><Citation>Caceres C.J., Seibert B., Cargnin Faccin F., Cardenas-Garcia S., Rajao D.S., Perez D.R. Influenza antivirals and animal models. FEBS Open Bio. 2022;12:1142–1165. doi: 10.1002/2211-5463.13416.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/2211-5463.13416</ArticleId><ArticleId IdType="pmc">PMC9157400</ArticleId><ArticleId IdType="pubmed">35451200</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang A., Chaudhari H., Agung Y., D’Agostino M.R., Ang J.C., Tugg Y., Miller M.S. Hemagglutinin stalk-binding antibodies enhance effectiveness of neuraminidase inhibitors against influenza via Fc-dependent effector functions. Cell Rep. Med. 2022;3:100718. doi: 10.1016/j.xcrm.2022.100718.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xcrm.2022.100718</ArticleId><ArticleId IdType="pmc">PMC9418849</ArticleId><ArticleId IdType="pubmed">35977467</ArticleId></ArticleIdList></Reference><Reference><Citation>Rota P.A., Wallis T.R., Harmon M.W., Rota J.S., Kendal A.P., Nerome K. Cocirculation of two distinct evolutionary lineages of influenza type B virus since 1983. Virology. 1990;175:59–68. doi: 10.1016/0042-6822(90)90186-U.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0042-6822(90)90186-U</ArticleId><ArticleId IdType="pubmed">2309452</ArticleId></ArticleIdList></Reference><Reference><Citation>Webster R.G., Laver W.G., Air G.M., Schild G.C. Molecular mechanisms of variation in influenza viruses. Nature. 1982;296:115–121. doi: 10.1038/296115a0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/296115a0</ArticleId><ArticleId IdType="pubmed">6174870</ArticleId></ArticleIdList></Reference><Reference><Citation>Krammer F., Smith G.J.D., Fouchier R.A.M., Peiris M., Kedzierska K., Doherty P.C., Palese P., Shaw M.L., Treanor J., Webster R.G., et al. Influenza. Nat. Rev. Dis. Primers. 2018;4:3. doi: 10.1038/s41572-018-0002-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41572-018-0002-y</ArticleId><ArticleId IdType="pmc">PMC7097467</ArticleId><ArticleId IdType="pubmed">29955068</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y., Xu C., Zhang H., Liu G.D., Xue C., Cao Y. Targeting Hemagglutinin: Approaches for Broad Protection against the Influenza A Virus. Viruses. 2019;11:405. doi: 10.3390/v11050405.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v11050405</ArticleId><ArticleId IdType="pmc">PMC6563292</ArticleId><ArticleId IdType="pubmed">31052339</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang W.C., Sayedahmed E.E., Sambhara S., Mittal S.K. Progress towards the Development of a Universal Influenza Vaccine. Viruses. 2022;14:1684. doi: 10.3390/v14081684.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v14081684</ArticleId><ArticleId IdType="pmc">PMC9415875</ArticleId><ArticleId IdType="pubmed">36016306</ArticleId></ArticleIdList></Reference><Reference><Citation>Bloom J.D., Gong L.I., Baltimore D. Permissive secondary mutations enable the evolution of influenza oseltamivir resistance. Science. 2010;328:1272–1275. doi: 10.1126/science.1187816.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1187816</ArticleId><ArticleId IdType="pmc">PMC2913718</ArticleId><ArticleId IdType="pubmed">20522774</ArticleId></ArticleIdList></Reference><Reference><Citation>Meijer A., Rebelo-de-Andrade H., Correia V., Besselaar T., Drager-Dayal R., Fry A., Gregory V., Gubareva L., Kageyama T., Lackenby A., et al. Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2012–2013. Antiviral Res. 2014;110:31–41. doi: 10.1016/j.antiviral.2014.07.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2014.07.001</ArticleId><ArticleId IdType="pmc">PMC8851378</ArticleId><ArticleId IdType="pubmed">25043638</ArticleId></ArticleIdList></Reference><Reference><Citation>Osterhaus A.D., Rimmelzwaan G.F., Martina B.E., Bestebroer T.M., Fouchier R.A. Influenza B virus in seals. Science. 2000;288:1051–1053. doi: 10.1126/science.288.5468.1051.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.288.5468.1051</ArticleId><ArticleId IdType="pubmed">10807575</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown I.H., Harris P.A., Alexander D.J. Serological studies of influenza viruses in pigs in Great Britain 1991-2. Epidemiol. Infect. 1995;114:511–520. doi: 10.1017/S0950268800052225.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S0950268800052225</ArticleId><ArticleId IdType="pmc">PMC2271297</ArticleId><ArticleId IdType="pubmed">7781739</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai C.P., Tsai H.J. Influenza B viruses in pigs, Taiwan. Influenza Other Respir. Viruses. 2019;13:91–105. doi: 10.1111/irv.12588.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/irv.12588</ArticleId><ArticleId IdType="pmc">PMC6304316</ArticleId><ArticleId IdType="pubmed">29996007</ArticleId></ArticleIdList></Reference><Reference><Citation>Long J.S., Mistry B., Haslam S.M., Barclay W.S. Host and viral determinants of influenza A virus species specificity. Nat. Rev. Microbiol. 2019;17:67–81. doi: 10.1038/s41579-018-0115-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-018-0115-z</ArticleId><ArticleId IdType="pubmed">30487536</ArticleId></ArticleIdList></Reference><Reference><Citation>Saunders-Hastings P.R., Krewski D. Reviewing the History of Pandemic Influenza: Understanding Patterns of Emergence and Transmission. Pathogens. 2016;5:66. doi: 10.3390/pathogens5040066.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pathogens5040066</ArticleId><ArticleId IdType="pmc">PMC5198166</ArticleId><ArticleId IdType="pubmed">27929449</ArticleId></ArticleIdList></Reference><Reference><Citation>Su S., Chaves S.S., Perez A., D’Mello T., Kirley P.D., Yousey-Hindes K., Farley M.M., Harris M., Sharangpani R., Lynfield R., et al. Comparing clinical characteristics between hospitalized adults with laboratory-confirmed influenza A and B virus infection. Clin. Infect. Dis. 2014;59:252–255. doi: 10.1093/cid/ciu269.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciu269</ArticleId><ArticleId IdType="pubmed">24748521</ArticleId></ArticleIdList></Reference><Reference><Citation>Avni T., Babich T., Nir A., Yahav D., Shaked H., Sorek N., Zvi H.B., Bishara J., Atamna A. Comparison of clinical outcomes of influenza A and B at the 2017–2018 influenza season: A cohort study. Eur. J. Clin. Microbiol. Infect. Dis. 2020;39:1109–1114. doi: 10.1007/s10096-020-03822-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10096-020-03822-x</ArticleId><ArticleId IdType="pmc">PMC7095355</ArticleId><ArticleId IdType="pubmed">31989376</ArticleId></ArticleIdList></Reference><Reference><Citation>Zaraket H., Hurt A.C., Clinch B., Barr I., Lee N. Burden of influenza B virus infection and considerations for clinical management. Antiviral Res. 2021;185:104970. doi: 10.1016/j.antiviral.2020.104970.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2020.104970</ArticleId><ArticleId IdType="pubmed">33159999</ArticleId></ArticleIdList></Reference><Reference><Citation>Shang M., Blanton L., Brammer L., Olsen S.J., Fry A.M. Influenza-Associated Pediatric Deaths in the United States, 2010–2016. Pediatrics. 2018;141:e20172918. doi: 10.1542/peds.2017-2918.</Citation><ArticleIdList><ArticleId IdType="doi">10.1542/peds.2017-2918</ArticleId><ArticleId IdType="pubmed">29440502</ArticleId></ArticleIdList></Reference><Reference><Citation>Read J.M., Zimmer S., Vukotich C., Jr., Schweizer M.L., Galloway D., Lingle C., Yearwood G., Calderone P., Noble E., Quadelacy T., et al. Influenza and other respiratory viral infections associated with absence from school among schoolchildren in Pittsburgh, Pennsylvania, USA: A cohort study. BMC Infect. Dis. 2021;21:291. doi: 10.1186/s12879-021-05922-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-021-05922-1</ArticleId><ArticleId IdType="pmc">PMC7983083</ArticleId><ArticleId IdType="pubmed">33752625</ArticleId></ArticleIdList></Reference><Reference><Citation>Yazici Özkaya P., Turanli E.E., Metin H., Aydın Uysal A., Çiçek C., Karapinar B. Severe influenza virus infection in children admitted to the PICU: Comparison of influenza A and influenza B virus infection. J. Med. Virol. 2022;94:575–581. doi: 10.1002/jmv.27400.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.27400</ArticleId><ArticleId IdType="pubmed">34655235</ArticleId></ArticleIdList></Reference><Reference><Citation>Dai Z., Fan K., Zhang L., Yang M., Yu Q., Liu L., Leung L. Risk factors for influenza B virus-associated pneumonia in adults. Am. J. Infect. Control. 2020;48:194–198. doi: 10.1016/j.ajic.2019.07.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajic.2019.07.010</ArticleId><ArticleId IdType="pubmed">31431289</ArticleId></ArticleIdList></Reference><Reference><Citation>Borchering R.K., Gunning C.E., Gokhale D.V., Weedop K.B., Saeidpour A., Brett T.S., Rohani P. Anomalous influenza seasonality in the United States and the emergence of novel influenza B viruses. Proc. Natl. Acad. Sci. USA. 2021;118:e2012327118. doi: 10.1073/pnas.2012327118.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2012327118</ArticleId><ArticleId IdType="pmc">PMC7865157</ArticleId><ArticleId IdType="pubmed">33495348</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu N., Zhang D., Wang W., Li X., Yang B., Song J., Zhao X., Huang B., Shi W., Lu R., et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N. Engl. J. Med. 2020;382:727–733. doi: 10.1056/NEJMoa2001017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2001017</ArticleId><ArticleId IdType="pmc">PMC7092803</ArticleId><ArticleId IdType="pubmed">31978945</ArticleId></ArticleIdList></Reference><Reference><Citation>Olsen S.J., Azziz-Baumgartner E., Budd A.P., Brammer L., Sullivan S., Pineda R.F., Cohen C., Fry A.M. Decreased Influenza Activity During the COVID-19 Pandemic—United States, Australia, Chile, and South Africa, 2020. MMWR Morb. Mortal. Wkly. Rep. 2020;69:1305–1309. doi: 10.15585/mmwr.mm6937a6.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm6937a6</ArticleId><ArticleId IdType="pmc">PMC7498167</ArticleId><ArticleId IdType="pubmed">32941415</ArticleId></ArticleIdList></Reference><Reference><Citation>Qi Y., Shaman J., Pei S. Quantifying the Impact of COVID-19 Nonpharmaceutical Interventions on Influenza Transmission in the United States. J. Infect. Dis. 2021;224:1500–1508. doi: 10.1093/infdis/jiab485.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiab485</ArticleId><ArticleId IdType="pmc">PMC8522386</ArticleId><ArticleId IdType="pubmed">34551108</ArticleId></ArticleIdList></Reference><Reference><Citation>Achangwa C., Park H., Ryu S., Lee M.-S. Collateral Impact of Public Health and Social Measures on Respiratory Virus Activity during the COVID-19 Pandemic 2020–2021. Viruses. 2022;14:1071. doi: 10.3390/v14051071.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v14051071</ArticleId><ArticleId IdType="pmc">PMC9146684</ArticleId><ArticleId IdType="pubmed">35632810</ArticleId></ArticleIdList></Reference><Reference><Citation>Takeuchi H., Kawashima R. Disappearance and Re-Emergence of Influenza during the COVID-19 Pandemic: Association with Infection Control Measures. Viruses. 2023;15:223. doi: 10.3390/v15010223.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v15010223</ArticleId><ArticleId IdType="pmc">PMC9862942</ArticleId><ArticleId IdType="pubmed">36680263</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuitunen I., Artama M., Haapanen M., Renko M. Rhinovirus spread in children during the COVID-19 pandemic despite social restrictions-A nationwide register study in Finland. J. Med. Virol. 2021;93:6063–6067. doi: 10.1002/jmv.27180.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.27180</ArticleId><ArticleId IdType="pmc">PMC8426983</ArticleId><ArticleId IdType="pubmed">34228369</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu P., Xu M., Cao L., Su L., Lu L., Dong N., Jia R., Zhu X., Xu J. Impact of COVID-19 pandemic on the prevalence of respiratory viruses in children with lower respiratory tract infections in China. Virol. J. 2021;18:159. doi: 10.1186/s12985-021-01627-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12985-021-01627-8</ArticleId><ArticleId IdType="pmc">PMC8329611</ArticleId><ArticleId IdType="pubmed">34344406</ArticleId></ArticleIdList></Reference><Reference><Citation>Uyeki T.M., Hui D.S., Zambon M., Wentworth D.E., Monto A.S. Influenza. Lancet. 2022;400:693–706. doi: 10.1016/S0140-6736(22)00982-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)00982-5</ArticleId><ArticleId IdType="pmc">PMC9411419</ArticleId><ArticleId IdType="pubmed">36030813</ArticleId></ArticleIdList></Reference><Reference><Citation>Foley D.A., Sikazwe C.T., Minney-Smith C.A., Ernst T., Moore H.C., Nicol M.P., Smith D.W., Levy A., Blyth C.C. An Unusual Resurgence of Human Metapneumovirus in Western Australia Following the Reduction of Non-Pharmaceutical Interventions to Prevent SARS-CoV-2 Transmission. Viruses. 2022;14:2135. doi: 10.3390/v14102135.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v14102135</ArticleId><ArticleId IdType="pmc">PMC9612024</ArticleId><ArticleId IdType="pubmed">36298690</ArticleId></ArticleIdList></Reference><Reference><Citation>Paget J., Caini S., Del Riccio M., van Waarden W., Meijer A. Has influenza B/Yamagata become extinct and what implications might this have for quadrivalent influenza vaccines? Euro Surveill. 2022;27:2200753. doi: 10.2807/1560-7917.ES.2022.27.39.2200753.</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.ES.2022.27.39.2200753</ArticleId><ArticleId IdType="pmc">PMC9524051</ArticleId><ArticleId IdType="pubmed">36177871</ArticleId></ArticleIdList></Reference><Reference><Citation>Francis T., Jr. A New Type of Virus from Epidemic Influenza. Science. 1940;92:405–408. doi: 10.1126/science.92.2392.405.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.92.2392.405</ArticleId><ArticleId IdType="pubmed">17794275</ArticleId></ArticleIdList></Reference><Reference><Citation>Rota P.A., Hemphill M.L., Whistler T., Regnery H.L., Kendal A.P. Antigenic and genetic characterization of the haemagglutinins of recent cocirculating strains of influenza B virus. Pt 10J. Gen. Virol. 1992;73:2737–2742. doi: 10.1099/0022-1317-73-10-2737.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/0022-1317-73-10-2737</ArticleId><ArticleId IdType="pubmed">1402807</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosu M.E., Lexmond P., Bestebroer T.M., Hauser B.M., Smith D.J., Herfst S., Fouchier R.A.M. Substitutions near the HA receptor binding site explain the origin and major antigenic change of the B/Victoria and B/Yamagata lineages. Proc. Natl. Acad. Sci. USA. 2022;119:e2211616119. doi: 10.1073/pnas.2211616119.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2211616119</ArticleId><ArticleId IdType="pmc">PMC9586307</ArticleId><ArticleId IdType="pubmed">36215486</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu X., Lindstrom S.E., Shaw M.W., Smith C.B., Hall H.E., Mungall B.A., Subbarao K., Cox N.J., Klimov A. Reassortment and evolution of current human influenza A and B viruses. Virus Res. 2004;103:55–60. doi: 10.1016/j.virusres.2004.02.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virusres.2004.02.013</ArticleId><ArticleId IdType="pubmed">15163489</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin Y.P., Gregory V., Bennett M., Hay A. Recent changes among human influenza viruses. Virus Res. 2004;103:47–52. doi: 10.1016/j.virusres.2004.02.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virusres.2004.02.011</ArticleId><ArticleId IdType="pubmed">15163487</ArticleId></ArticleIdList></Reference><Reference><Citation>Vijaykrishna D., Holmes E.C., Joseph U., Fourment M., Su Y.C., Halpin R., Lee R.T., Deng Y.M., Gunalan V., Lin X., et al. The contrasting phylodynamics of human influenza B viruses. eLife. 2015;4:e05055. doi: 10.7554/eLife.05055.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.05055</ArticleId><ArticleId IdType="pmc">PMC4383373</ArticleId><ArticleId IdType="pubmed">25594904</ArticleId></ArticleIdList></Reference><Reference><Citation>Langat P., Raghwani J., Dudas G., Bowden T.A., Edwards S., Gall A., Bedford T., Rambaut A., Daniels R.S., Russell C.A., et al. Genome-wide evolutionary dynamics of influenza B viruses on a global scale. PLoS Pathog. 2017;13:e1006749. doi: 10.1371/journal.ppat.1006749.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1006749</ArticleId><ArticleId IdType="pmc">PMC5790164</ArticleId><ArticleId IdType="pubmed">29284042</ArticleId></ArticleIdList></Reference><Reference><Citation>Virk R.K., Jayakumar J., Mendenhall I.H., Moorthy M., Lam P., Linster M., Lim J., Lin C., Oon L.L.E., Lee H.K., et al. Divergent evolutionary trajectories of influenza B viruses underlie their contemporaneous epidemic activity. Proc. Natl. Acad. Sci. USA. 2020;117:619–628. doi: 10.1073/pnas.1916585116.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1916585116</ArticleId><ArticleId IdType="pmc">PMC6955377</ArticleId><ArticleId IdType="pubmed">31843889</ArticleId></ArticleIdList></Reference><Reference><Citation>Zou S., Prud’homme I., Weber J.M. Evolution of the hemagglutinin gene of influenza B virus was driven by both positive and negative selection pressures. Virus Genes. 1997;14:181–185. doi: 10.1023/a:1007927725332.</Citation><ArticleIdList><ArticleId IdType="doi">10.1023/a:1007927725332</ArticleId><ArticleId IdType="pubmed">9311562</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q., Cheng F., Lu M., Tian X., Ma J. Crystal structure of unliganded influenza B virus hemagglutinin. J. Virol. 2008;82:3011–3020. doi: 10.1128/JVI.02477-07.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02477-07</ArticleId><ArticleId IdType="pmc">PMC2259021</ArticleId><ArticleId IdType="pubmed">18184701</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun W., Kang D.S., Zheng A., Liu S.T.H., Broecker F., Simon V., Krammer F., Palese P. Antibody Responses toward the Major Antigenic Sites of Influenza B Virus Hemagglutinin in Mice, Ferrets, and Humans. J. Virol. 2019;93:e01673-18. doi: 10.1128/JVI.01673-18.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01673-18</ArticleId><ArticleId IdType="pmc">PMC6321909</ArticleId><ArticleId IdType="pubmed">30381487</ArticleId></ArticleIdList></Reference><Reference><Citation>Fulton B.O., Sun W., Heaton N.S., Palese P. The Influenza B Virus Hemagglutinin Head Domain Is Less Tolerant to Transposon Mutagenesis than That of the Influenza A Virus. J. Virol. 2018;92:e00754-18. doi: 10.1128/JVI.00754-18.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00754-18</ArticleId><ArticleId IdType="pmc">PMC6069205</ArticleId><ArticleId IdType="pubmed">29899093</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrova V.N., Russell C.A. The evolution of seasonal influenza viruses. Nat. Rev. Microbiol. 2018;16:47–60. doi: 10.1038/nrmicro.2017.118.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrmicro.2017.118</ArticleId><ArticleId IdType="pubmed">29109554</ArticleId></ArticleIdList></Reference><Reference><Citation>Valesano A.L., Fitzsimmons W.J., McCrone J.T., Petrie J.G., Monto A.S., Martin E.T., Lauring A.S. Influenza B Viruses Exhibit Lower Within-Host Diversity than Influenza A Viruses in Human Hosts. J. Virol. 2020;94:e01710-19. doi: 10.1128/JVI.01710-19.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01710-19</ArticleId><ArticleId IdType="pmc">PMC7022338</ArticleId><ArticleId IdType="pubmed">31801858</ArticleId></ArticleIdList></Reference><Reference><Citation>Nobusawa E., Sato K. Comparison of the mutation rates of human influenza A and B viruses. J. Virol. 2006;80:3675–3678. doi: 10.1128/JVI.80.7.3675-3678.2006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.80.7.3675-3678.2006</ArticleId><ArticleId IdType="pmc">PMC1440390</ArticleId><ArticleId IdType="pubmed">16537638</ArticleId></ArticleIdList></Reference><Reference><Citation>Bedford T., Riley S., Barr I.G., Broor S., Chadha M., Cox N.J., Daniels R.S., Gunasekaran C.P., Hurt A.C., Kelso A., et al. Global circulation patterns of seasonal influenza viruses vary with antigenic drift. Nature. 2015;523:217–220. doi: 10.1038/nature14460.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature14460</ArticleId><ArticleId IdType="pmc">PMC4499780</ArticleId><ArticleId IdType="pubmed">26053121</ArticleId></ArticleIdList></Reference><Reference><Citation>Caini S., Huang Q.S., Ciblak M.A., Kusznierz G., Owen R., Wangchuk S., Henriques C.M., Njouom R., Fasce R.A., Yu H., et al. Epidemiological and virological characteristics of influenza B: Results of the Global Influenza B Study. Influenza Other Respir. Viruses. 2015;9((Suppl. 1)):3–12. doi: 10.1111/irv.12319.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/irv.12319</ArticleId><ArticleId IdType="pmc">PMC4549097</ArticleId><ArticleId IdType="pubmed">26256290</ArticleId></ArticleIdList></Reference><Reference><Citation>Caini S., Kusznierz G., Garate V.V., Wangchuk S., Thapa B., de Paula Júnior F.J., Ferreira de Almeida W.A., Njouom R., Fasce R.A., Bustos P., et al. The epidemiological signature of influenza B virus and its B/Victoria and B/Yamagata lineages in the 21st century. PLoS ONE. 2019;14:e0222381. doi: 10.1371/journal.pone.0222381.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0222381</ArticleId><ArticleId IdType="pmc">PMC6742362</ArticleId><ArticleId IdType="pubmed">31513690</ArticleId></ArticleIdList></Reference><Reference><Citation>Campbell A.P., Ogokeh C., Weinberg G.A., Boom J.A., Englund J.A., Williams J.V., Halasa N.B., Selvarangan R., Staat M.A., Klein E.J., et al. Effect of Vaccination on Preventing Influenza-Associated Hospitalizations among Children during a Severe Season Associated with B/Victoria Viruses, 2019–2020. Clin. Infect. Dis. 2021;73:e947–e954. doi: 10.1093/cid/ciab060.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciab060</ArticleId><ArticleId IdType="pubmed">33502489</ArticleId></ArticleIdList></Reference><Reference><Citation>Miron V.D., Bănică L., Săndulescu O., Paraschiv S., Surleac M., Florea D., Vlaicu O., Milu P., Streinu-Cercel A., Bilașco A., et al. Clinical and molecular epidemiology of influenza viruses from Romanian patients hospitalized during the 2019/20 season. PLoS ONE. 2021;16:e0258798. doi: 10.1371/journal.pone.0258798.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0258798</ArticleId><ArticleId IdType="pmc">PMC8589178</ArticleId><ArticleId IdType="pubmed">34767579</ArticleId></ArticleIdList></Reference><Reference><Citation>Boonnak K., Mansanguan C., Schuerch D., Boonyuen U., Lerdsamran H., Jiamsomboon K., Sae Wang F., Huntrup A., Prasertsopon J., Kosoltanapiwat N., et al. Molecular Characterization of Seasonal Influenza A and B from Hospitalized Patients in Thailand in 2018–2019. Viruses. 2021;13:977. doi: 10.3390/v13060977.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v13060977</ArticleId><ArticleId IdType="pmc">PMC8228477</ArticleId><ArticleId IdType="pubmed">34070388</ArticleId></ArticleIdList></Reference><Reference><Citation>Heider A., Wedde M., Dürrwald R., Wolff T., Schweiger B. Molecular characterization and evolution dynamics of influenza B viruses circulating in Germany from season 1996/1997 to 2019/2020. Virus Res. 2022;322:198926. doi: 10.1016/j.virusres.2022.198926.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virusres.2022.198926</ArticleId><ArticleId IdType="pubmed">36096395</ArticleId></ArticleIdList></Reference><Reference><Citation>US Centers for Disease Control  FluView Interactive; National, Regional, and State Level Outpatient Illness and Viral Surveillance.  [(accessed on 5 June 2024)]; Available online:  https://gis.cdc.gov/grasp/fluview/fluportaldashboard.html.</Citation></Reference><Reference><Citation>Koutsakos M., Wheatley A.K., Laurie K., Kent S.J., Rockman S. Influenza lineage extinction during the COVID-19 pandemic? Nat. Rev. Microbiol. 2021;19:741–742. doi: 10.1038/s41579-021-00642-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-021-00642-4</ArticleId><ArticleId IdType="pmc">PMC8477979</ArticleId><ArticleId IdType="pubmed">34584246</ArticleId></ArticleIdList></Reference><Reference><Citation>Monto A.S., Zambon M., Weir J.P. The End of B/Yamagata Influenza Transmission—Transitioning from Quadrivalent Vaccines. N. Engl. J. Med. 2024;390:1256–1258. doi: 10.1056/NEJMp2314801.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMp2314801</ArticleId><ArticleId IdType="pubmed">38416423</ArticleId></ArticleIdList></Reference><Reference><Citation>Koutsakos M., Rockman S., Krammer F. Is eradication of influenza B viruses possible? Lancet Infect. Dis. 2024;24:451–453. doi: 10.1016/S1473-3099(24)00132-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(24)00132-4</ArticleId><ArticleId IdType="pubmed">38452776</ArticleId></ArticleIdList></Reference><Reference><Citation>Skowronski D.M., Masaro C., Kwindt T.L., Mak A., Petric M., Li Y., Sebastian R., Chong M., Tam T., De Serres G. Estimating vaccine effectiveness against laboratory-confirmed influenza using a sentinel physician network: Results from the 2005–2006 season of dual A and B vaccine mismatch in Canada. Vaccine. 2007;25:2842–2851. doi: 10.1016/j.vaccine.2006.10.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2006.10.002</ArticleId><ArticleId IdType="pubmed">17081662</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson L.A., Gaglani M.J., Keyserling H.L., Balser J., Bouveret N., Fries L., Treanor J.J. Safety, efficacy, and immunogenicity of an inactivated influenza vaccine in healthy adults: A randomized, placebo-controlled trial over two influenza seasons. BMC Infect. Dis. 2010;10:71. doi: 10.1186/1471-2334-10-71.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2334-10-71</ArticleId><ArticleId IdType="pmc">PMC2845585</ArticleId><ArticleId IdType="pubmed">20236548</ArticleId></ArticleIdList></Reference><Reference><Citation>Lo Y.C., Chuang J.H., Kuo H.W., Huang W.T., Hsu Y.F., Liu M.T., Chen C.H., Huang H.H., Chang C.H., Chou J.H., et al. Surveillance and vaccine effectiveness of an influenza epidemic predominated by vaccine-mismatched influenza B/Yamagata-lineage viruses in Taiwan, 2011–2012 season. PLoS ONE. 2013;8:e58222. doi: 10.1371/journal.pone.0058222.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0058222</ArticleId><ArticleId IdType="pmc">PMC3589334</ArticleId><ArticleId IdType="pubmed">23472161</ArticleId></ArticleIdList></Reference><Reference><Citation>Costa J.C.D., Siqueira M.M., Brown D., Lopes J.O., Costa B.C.D., Gama E.L., Aguiar-Oliveira M.L. Vaccine Mismatches, Viral Circulation, and Clinical Severity Patterns of Influenza B Victoria and Yamagata Infections in Brazil over the Decade 2010–2020: A Statistical and Phylogeny-Trait Analyses. Viruses. 2022;14:1477. doi: 10.3390/v14071477.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v14071477</ArticleId><ArticleId IdType="pmc">PMC9321334</ArticleId><ArticleId IdType="pubmed">35891457</ArticleId></ArticleIdList></Reference><Reference><Citation>FDA, U.S. Fluzone, Fluzone High-Dose and Fluzone Intradermal.  [(accessed on 13 January 2024)]; Available online:  https://www.fda.gov/vaccines-blood-biologics/vaccines/fluzone-fluzone-high-dose-and-fluzone-intradermal.</Citation></Reference><Reference><Citation>Zimmerman R.K., Nowalk M.P., Chung J., Jackson M.L., Jackson L.A., Petrie J.G., Monto A.S., McLean H.Q., Belongia E.A., Gaglani M., et al. 2014–2015 Influenza Vaccine Effectiveness in the United States by Vaccine Type. Clin. Infect. Dis. 2016;63:1564–1573. doi: 10.1093/cid/ciw635.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciw635</ArticleId><ArticleId IdType="pmc">PMC5146719</ArticleId><ArticleId IdType="pubmed">27702768</ArticleId></ArticleIdList></Reference><Reference><Citation>Flannery B., Kondor R.J.G., Chung J.R., Gaglani M., Reis M., Zimmerman R.K., Nowalk M.P., Jackson M.L., Jackson L.A., Monto A.S., et al. Spread of Antigenically Drifted Influenza A(H3N2) Viruses and Vaccine Effectiveness in the United States During the 2018–2019 Season. J. Infect. Dis. 2019;221:8–15. doi: 10.1093/infdis/jiz543.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiz543</ArticleId><ArticleId IdType="pmc">PMC7325528</ArticleId><ArticleId IdType="pubmed">31665373</ArticleId></ArticleIdList></Reference><Reference><Citation>Tenforde M.W., Kondor R.J.G., Chung J.R., Zimmerman R.K., Nowalk M.P., Jackson M.L., Jackson L.A., Monto A.S., Martin E.T., Belongia E.A., et al. Effect of Antigenic Drift on Influenza Vaccine Effectiveness in the United States-2019–2020. Clin. Infect. Dis. 2021;73:e4244–e4250. doi: 10.1093/cid/ciaa1884.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciaa1884</ArticleId><ArticleId IdType="pmc">PMC8664438</ArticleId><ArticleId IdType="pubmed">33367650</ArticleId></ArticleIdList></Reference><Reference><Citation>Castrucci M.R. Factors affecting immune responses to the influenza vaccine. Hum. Vaccines Immunother. 2018;14:637–646. doi: 10.1080/21645515.2017.1338547.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2017.1338547</ArticleId><ArticleId IdType="pmc">PMC5861809</ArticleId><ArticleId IdType="pubmed">28617077</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajaram S., Wojcik R., Moore C., Ortiz de Lejarazu R., de Lusignan S., Montomoli E., Rossi A., Pérez-Rubio A., Trilla A., Baldo V., et al. The impact of candidate influenza virus and egg-based manufacture on vaccine effectiveness: Literature review and expert consensus. Vaccine. 2020;38:6047–6056. doi: 10.1016/j.vaccine.2020.06.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2020.06.021</ArticleId><ArticleId IdType="pubmed">32600916</ArticleId></ArticleIdList></Reference><Reference><Citation>Jang Y.H., Seong B.L. The Quest for a Truly Universal Influenza Vaccine. Front. Cell Infect. Microbiol. 2019;9:344. doi: 10.3389/fcimb.2019.00344.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcimb.2019.00344</ArticleId><ArticleId IdType="pmc">PMC6795694</ArticleId><ArticleId IdType="pubmed">31649895</ArticleId></ArticleIdList></Reference><Reference><Citation>Essink B.J., Heeringa M., Jeanfreau R.J., Finn D., Matassa V., Edelman J., Hohenboken M., Molrine D. Safety and Immunogenicity of Cell-Based Quadrivalent Influenza Vaccine: A Randomized Trial. Pediatrics. 2022;150:e2022057509. doi: 10.1542/peds.2022-057509.</Citation><ArticleIdList><ArticleId IdType="doi">10.1542/peds.2022-057509</ArticleId><ArticleId IdType="pubmed">36214072</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen J.Y., Hsieh S.M., Hwang S.J., Liu C.S., Li X., Fournier M., Yeh T.Y., Yin J.K., Samson S.I. Immunogenicity and safety of high-dose quadrivalent influenza vaccine in older adults in Taiwan: A phase III, randomized, multi-center study. Vaccine. 2022;40:6450–6454. doi: 10.1016/j.vaccine.2022.09.078.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2022.09.078</ArticleId><ArticleId IdType="pubmed">36216650</ArticleId></ArticleIdList></Reference><Reference><Citation>Vanni T., da Graça Salomão M., Viscondi J.Y.K., Braga P.E., da Silva A., de Oliveira Piorelli R., do Prado Santos J., Gattás V.L., Lucchesi M.B.B., de Oliveira M.M.M., et al. A randomized, double-blind, non-inferiority trial comparing the immunogenicity and safety of two seasonal inactivated influenza vaccines in adults. Vaccine. 2023;41:3454–3460. doi: 10.1016/j.vaccine.2023.04.050.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2023.04.050</ArticleId><ArticleId IdType="pubmed">37121800</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyce T.G., Levine M.Z., McClure D.L., King J.P., Flannery B., Nguyen H.Q., Belongia E.A. Antibody response to sequential vaccination with cell culture, recombinant, or egg-based influenza vaccines among U.S. adults. Hum. Vaccin Immunother. 2024;20:2370087. doi: 10.1080/21645515.2024.2370087.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2024.2370087</ArticleId><ArticleId IdType="pmc">PMC11238913</ArticleId><ArticleId IdType="pubmed">38982712</ArticleId></ArticleIdList></Reference><Reference><Citation>Heaton N.S., Sachs D., Chen C.J., Hai R., Palese P. Genome-wide mutagenesis of influenza virus reveals unique plasticity of the hemagglutinin and NS1 proteins. Proc. Natl. Acad. Sci. USA. 2013;110:20248–20253. doi: 10.1073/pnas.1320524110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1320524110</ArticleId><ArticleId IdType="pmc">PMC3864309</ArticleId><ArticleId IdType="pubmed">24277853</ArticleId></ArticleIdList></Reference><Reference><Citation>Krammer F., Pica N., Hai R., Margine I., Palese P. Chimeric hemagglutinin influenza virus vaccine constructs elicit broadly protective stalk-specific antibodies. J. Virol. 2013;87:6542–6550. doi: 10.1128/JVI.00641-13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00641-13</ArticleId><ArticleId IdType="pmc">PMC3676110</ArticleId><ArticleId IdType="pubmed">23576508</ArticleId></ArticleIdList></Reference><Reference><Citation>Ermler M.E., Kirkpatrick E., Sun W., Hai R., Amanat F., Chromikova V., Palese P., Krammer F. Chimeric Hemagglutinin Constructs Induce Broad Protection against Influenza B Virus Challenge in the Mouse Model. J. Virol. 2017;91:e00286-17. doi: 10.1128/JVI.00286-17.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00286-17</ArticleId><ArticleId IdType="pmc">PMC5446656</ArticleId><ArticleId IdType="pubmed">28356526</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun W., Kirkpatrick E., Ermler M., Nachbagauer R., Broecker F., Krammer F., Palese P. Development of Influenza B Universal Vaccine Candidates Using the “Mosaic” Hemagglutinin Approach. J. Virol. 2019;93:e00333-19. doi: 10.1128/JVI.00333-19.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00333-19</ArticleId><ArticleId IdType="pmc">PMC6613766</ArticleId><ArticleId IdType="pubmed">30944178</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y., Strohmeier S., González-Domínguez I., Tan J., Simon V., Krammer F., García-Sastre A., Palese P., Sun W. Mosaic Hemagglutinin-Based Whole Inactivated Virus Vaccines Induce Broad Protection Against Influenza B Virus Challenge in Mice. Front. Immunol. 2021;12:746447. doi: 10.3389/fimmu.2021.746447.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.746447</ArticleId><ArticleId IdType="pmc">PMC8481571</ArticleId><ArticleId IdType="pubmed">34603333</ArticleId></ArticleIdList></Reference><Reference><Citation>Song Y., Zhu W., Wang Y., Deng L., Ma Y., Dong C., Gonzalez G.X., Kim J., Wei L., Kang S.M., et al. Layered protein nanoparticles containing influenza B HA stalk induced sustained cross-protection against viruses spanning both viral lineages. Biomaterials. 2022;287:121664. doi: 10.1016/j.biomaterials.2022.121664.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biomaterials.2022.121664</ArticleId><ArticleId IdType="pmc">PMC9822777</ArticleId><ArticleId IdType="pubmed">35810540</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardenas-Garcia S., Caceres C.J., Rajao D., Perez D.R. Reverse genetics for influenza B viruses and recent advances in vaccine development. Curr. Opin. Virol. 2020;44:191–202. doi: 10.1016/j.coviro.2020.10.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.coviro.2020.10.005</ArticleId><ArticleId IdType="pmc">PMC8693393</ArticleId><ArticleId IdType="pubmed">33254031</ArticleId></ArticleIdList></Reference><Reference><Citation>Arevalo C.P., Bolton M.J., Le Sage V., Ye N., Furey C., Muramatsu H., Alameh M.G., Pardi N., Drapeau E.M., Parkhouse K., et al. A multivalent nucleoside-modified mRNA vaccine against all known influenza virus subtypes. Science. 2022;378:899–904. doi: 10.1126/science.abm0271.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abm0271</ArticleId><ArticleId IdType="pmc">PMC10790309</ArticleId><ArticleId IdType="pubmed">36423275</ArticleId></ArticleIdList></Reference><Reference><Citation>Pardi N., Carreño J.M., O’Dell G., Tan J., Bajusz C., Muramatsu H., Rijnink W., Strohmeier S., Loganathan M., Bielak D., et al. Development of a pentavalent broadly protective nucleoside-modified mRNA vaccine against influenza B viruses. Nat. Commun. 2022;13:4677. doi: 10.1038/s41467-022-32149-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-32149-8</ArticleId><ArticleId IdType="pmc">PMC9362976</ArticleId><ArticleId IdType="pubmed">35945226</ArticleId></ArticleIdList></Reference><Reference><Citation>Wohlbold T.J., Nachbagauer R., Xu H., Tan G.S., Hirsh A., Brokstad K.A., Cox R.J., Palese P., Krammer F. Vaccination with adjuvanted recombinant neuraminidase induces broad heterologous, but not heterosubtypic, cross-protection against influenza virus infection in mice. mBio. 2015;6:e02556. doi: 10.1128/mBio.02556-14.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mBio.02556-14</ArticleId><ArticleId IdType="pmc">PMC4453582</ArticleId><ArticleId IdType="pubmed">25759506</ArticleId></ArticleIdList></Reference><Reference><Citation>McMahon M., Kirkpatrick E., Stadlbauer D., Strohmeier S., Bouvier N.M., Krammer F. Mucosal Immunity against Neuraminidase Prevents Influenza B Virus Transmission in Guinea Pigs. mBio. 2019;10:e00560-19. doi: 10.1128/mBio.00560-19.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mBio.00560-19</ArticleId><ArticleId IdType="pmc">PMC6529633</ArticleId><ArticleId IdType="pubmed">31113896</ArticleId></ArticleIdList></Reference><Reference><Citation>Portela Catani J.P., Ysenbaert T., Smet A., Vuylsteke M., Vogel T.U., Saelens X. Anti-neuraminidase and anti-hemagglutinin immune serum can confer inter-lineage cross protection against recent influenza B. PLoS ONE. 2023;18:e0280825. doi: 10.1371/journal.pone.0280825.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0280825</ArticleId><ArticleId IdType="pmc">PMC9870131</ArticleId><ArticleId IdType="pubmed">36689429</ArticleId></ArticleIdList></Reference><Reference><Citation>Do T.H.T., Wheatley A.K., Kent S.J., Koutsakos M. Influenza B virus neuraminidase: A potential target for next-generation vaccines? Expert Rev. Vaccines. 2024;23:39–48. doi: 10.1080/14760584.2023.2290691.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14760584.2023.2290691</ArticleId><ArticleId IdType="pubmed">38037386</ArticleId></ArticleIdList></Reference><Reference><Citation>McMahon M., Tan J., O’Dell G., Kirkpatrick Roubidoux E., Strohmeier S., Krammer F. Immunity induced by vaccination with recombinant influenza B virus neuraminidase protein breaks viral transmission chains in guinea pigs in an exposure intensity-dependent manner. J. Virol. 2023;97:e0105723. doi: 10.1128/jvi.01057-23.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.01057-23</ArticleId><ArticleId IdType="pmc">PMC10617433</ArticleId><ArticleId IdType="pubmed">37800945</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X., Ross T.M. Anti-neuraminidase immunity in the combat against influenza. Expert Rev. Vaccines. 2024;23:474–484. doi: 10.1080/14760584.2024.2343689.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14760584.2024.2343689</ArticleId><ArticleId IdType="pmc">PMC11157429</ArticleId><ArticleId IdType="pubmed">38632930</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu N.C., Ellebedy A.H. Targeting neuraminidase: The next frontier for broadly protective influenza vaccines. Trends Immunol. 2024;45:11–19. doi: 10.1016/j.it.2023.11.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.it.2023.11.001</ArticleId><ArticleId IdType="pmc">PMC10841738</ArticleId><ArticleId IdType="pubmed">38103991</ArticleId></ArticleIdList></Reference><Reference><Citation>Nachbagauer R., Krammer F. Universal influenza virus vaccines and therapeutic antibodies. Clin. Microbiol. Infect. 2017;23:222–228. doi: 10.1016/j.cmi.2017.02.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2017.02.009</ArticleId><ArticleId IdType="pmc">PMC5389886</ArticleId><ArticleId IdType="pubmed">28216325</ArticleId></ArticleIdList></Reference><Reference><Citation>Freyn A.W., Ramos da Silva J., Rosado V.C., Bliss C.M., Pine M., Mui B.L., Tam Y.K., Madden T.D., de Souza Ferreira L.C., Weissman D., et al. A Multi-Targeting, Nucleoside-Modified mRNA Influenza Virus Vaccine Provides Broad Protection in Mice. Mol. Ther. 2020;28:1569–1584. doi: 10.1016/j.ymthe.2020.04.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymthe.2020.04.018</ArticleId><ArticleId IdType="pmc">PMC7335735</ArticleId><ArticleId IdType="pubmed">32359470</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee S.Y., Kang J.O., Chang J. Nucleoprotein vaccine induces cross-protective cytotoxic T lymphocytes against both lineages of influenza B virus. Clin. Exp. Vaccine Res. 2019;8:54–63. doi: 10.7774/cevr.2019.8.1.54.</Citation><ArticleIdList><ArticleId IdType="doi">10.7774/cevr.2019.8.1.54</ArticleId><ArticleId IdType="pmc">PMC6369129</ArticleId><ArticleId IdType="pubmed">30775351</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung H., Kim E.A., Chang J. A “Prime and Deploy” Strategy for Universal Influenza Vaccine Targeting Nucleoprotein Induces Lung-Resident Memory CD8 T cells. Immune Netw. 2021;21:e28. doi: 10.4110/in.2021.21.e28.</Citation><ArticleIdList><ArticleId IdType="doi">10.4110/in.2021.21.e28</ArticleId><ArticleId IdType="pmc">PMC8410988</ArticleId><ArticleId IdType="pubmed">34522441</ArticleId></ArticleIdList></Reference><Reference><Citation>Ichihashi T., Yoshida R., Sugimoto C., Takada A., Kajino K. Cross-Protective Peptide Vaccine against Influenza A Viruses Developed in HLA-A*2402 Human Immunity Model. PLoS ONE. 2011;6:e24626. doi: 10.1371/journal.pone.0024626.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0024626</ArticleId><ArticleId IdType="pmc">PMC3176274</ArticleId><ArticleId IdType="pubmed">21949735</ArticleId></ArticleIdList></Reference><Reference><Citation>Crowe S.R., Miller S.C., Shenyo R.M., Woodland D.L. Vaccination with an acidic polymerase epitope of influenza virus elicits a potent antiviral T cell response but delayed clearance of an influenza virus challenge. J. Immunol. 2005;174:696–701. doi: 10.4049/jimmunol.174.2.696.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.174.2.696</ArticleId><ArticleId IdType="pubmed">15634888</ArticleId></ArticleIdList></Reference><Reference><Citation>Carascal M.B., Pavon R.D.N., Rivera W.L. Recent Progress in Recombinant Influenza Vaccine Development toward Heterosubtypic Immune Response. Front. Immunol. 2022;13:878943. doi: 10.3389/fimmu.2022.878943.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.878943</ArticleId><ArticleId IdType="pmc">PMC9162156</ArticleId><ArticleId IdType="pubmed">35663997</ArticleId></ArticleIdList></Reference><Reference><Citation>Gravel C., Muralidharan A., Duran A., Zetner A., Pfeifle A., Zhang W., Hashem A., Tamming L., Farnsworth A., Loemba H., et al. Synthetic vaccine affords full protection to mice against lethal challenge of influenza B virus of both genetic lineages. iScience. 2021;24:103328. doi: 10.1016/j.isci.2021.103328.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.isci.2021.103328</ArticleId><ArticleId IdType="pmc">PMC8586812</ArticleId><ArticleId IdType="pubmed">34805790</ArticleId></ArticleIdList></Reference><Reference><Citation>Weaver E.A., Rubrum A.M., Webby R.J., Barry M.A. Protection against divergent influenza H1N1 virus by a centralized influenza hemagglutinin. PLoS ONE. 2011;6:e18314. doi: 10.1371/journal.pone.0018314.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0018314</ArticleId><ArticleId IdType="pmc">PMC3065472</ArticleId><ArticleId IdType="pubmed">21464940</ArticleId></ArticleIdList></Reference><Reference><Citation>Webby R.J., Weaver E.A. Centralized Consensus Hemagglutinin Genes Induce Protective Immunity against H1, H3 and H5 Influenza Viruses. PLoS ONE. 2015;10:e0140702. doi: 10.1371/journal.pone.0140702.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0140702</ArticleId><ArticleId IdType="pmc">PMC4607479</ArticleId><ArticleId IdType="pubmed">26469190</ArticleId></ArticleIdList></Reference><Reference><Citation>Lingel A., Bullard B.L., Weaver E.A. Efficacy of an Adenoviral Vectored Multivalent Centralized Influenza Vaccine. Sci. Rep. 2017;7:14912. doi: 10.1038/s41598-017-14891-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-14891-y</ArticleId><ArticleId IdType="pmc">PMC5668234</ArticleId><ArticleId IdType="pubmed">29097763</ArticleId></ArticleIdList></Reference><Reference><Citation>Petro-Turnquist E.M., Bullard B.L., Pekarek M.J., Weaver E.A. Adenoviral-Vectored Centralized Consensus Hemagglutinin Vaccine Provides Broad Protection against H2 Influenza a Virus. Vaccines. 2022;10:926. doi: 10.3390/vaccines10060926.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines10060926</ArticleId><ArticleId IdType="pmc">PMC9229510</ArticleId><ArticleId IdType="pubmed">35746534</ArticleId></ArticleIdList></Reference><Reference><Citation>Giles B.M., Ross T.M. A computationally optimized broadly reactive antigen (COBRA) based H5N1 VLP vaccine elicits broadly reactive antibodies in mice and ferrets. Vaccine. 2011;29:3043–3054. doi: 10.1016/j.vaccine.2011.01.100.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2011.01.100</ArticleId><ArticleId IdType="pmc">PMC3090662</ArticleId><ArticleId IdType="pubmed">21320540</ArticleId></ArticleIdList></Reference><Reference><Citation>Giles B.M., Crevar C.J., Carter D.M., Bissel S.J., Schultz-Cherry S., Wiley C.A., Ross T.M. A Computationally Optimized Hemagglutinin Virus-Like Particle Vaccine Elicits Broadly Reactive Antibodies that Protect Nonhuman Primates from H5N1 Infection. J. Infect. Dis. 2012;205:1562–1570. doi: 10.1093/infdis/jis232.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jis232</ArticleId><ArticleId IdType="pmc">PMC3415819</ArticleId><ArticleId IdType="pubmed">22448011</ArticleId></ArticleIdList></Reference><Reference><Citation>Carter D.M., Darby C.A., Lefoley B.C., Crevar C.J., Alefantis T., Oomen R., Anderson S.F., Strugnell T., Cortés-Garcia G., Vogel T.U., et al. Design and Characterization of a Computationally Optimized Broadly Reactive Hemagglutinin Vaccine for H1N1 Influenza Viruses. J. Virol. 2016;90:4720–4734. doi: 10.1128/JVI.03152-15.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.03152-15</ArticleId><ArticleId IdType="pmc">PMC4836330</ArticleId><ArticleId IdType="pubmed">26912624</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong T.M., Allen J.D., Bebin-Blackwell A.G., Carter D.M., Alefantis T., DiNapoli J., Kleanthous H., Ross T.M. Computationally Optimized Broadly Reactive Hemagglutinin Elicits Hemagglutination Inhibition Antibodies against a Panel of H3N2 Influenza Virus Cocirculating Variants. J. Virol. 2017;91:e01581-17. doi: 10.1128/JVI.01581-17.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01581-17</ArticleId><ArticleId IdType="pmc">PMC5709590</ArticleId><ArticleId IdType="pubmed">28978710</ArticleId></ArticleIdList></Reference><Reference><Citation>Allen J.D., Ray S., Ross T.M. Split inactivated COBRA vaccine elicits protective antibodies against H1N1 and H3N2 influenza viruses. PLoS ONE. 2018;13:e0204284. doi: 10.1371/journal.pone.0204284.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0204284</ArticleId><ArticleId IdType="pmc">PMC6161894</ArticleId><ArticleId IdType="pubmed">30265682</ArticleId></ArticleIdList></Reference><Reference><Citation>Skarlupka A.L., Owino S.O., Suzuki-Williams L.P., Crevar C.J., Carter D.M., Ross T.M. Computationally optimized broadly reactive vaccine based upon swine H1N1 influenza hemagglutinin sequences protects against both swine and human isolated viruses. Hum. Vaccin. Immunother. 2019;15:2013–2029. doi: 10.1080/21645515.2019.1653743.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2019.1653743</ArticleId><ArticleId IdType="pmc">PMC6773400</ArticleId><ArticleId IdType="pubmed">31448974</ArticleId></ArticleIdList></Reference><Reference><Citation>Reneer Z.B., Jamieson P.J., Skarlupka A.L., Huang Y., Ross T.M. Computationally Optimized Broadly Reactive H2 HA Influenza Vaccines Elicited Broadly Cross-Reactive Antibodies and Protected Mice from Viral Challenges. J. Virol. 2020;95:e01526-20. doi: 10.1128/JVI.01526-20.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01526-20</ArticleId><ArticleId IdType="pmc">PMC7944441</ArticleId><ArticleId IdType="pubmed">33115871</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertran K., Kassa A., Criado M.F., Nuñez I.A., Lee D.H., Killmaster L., e Silva M.S., Ross T.M., Mebatsion T., Pritchard N., et al. Efficacy of recombinant Marek’s disease virus vectored vaccines with computationally optimized broadly reactive antigen (COBRA) hemagglutinin insert against genetically diverse H5 high pathogenicity avian influenza viruses. Vaccine. 2021;39:1933–1942. doi: 10.1016/j.vaccine.2021.02.075.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2021.02.075</ArticleId><ArticleId IdType="pubmed">33715903</ArticleId></ArticleIdList></Reference><Reference><Citation>Reneer Z.B., Skarlupka A.L., Jamieson P.J., Ross T.M. Broadly Reactive H2 Hemagglutinin Vaccines Elicit Cross-Reactive Antibodies in Ferrets Preimmune to Seasonal Influenza A Viruses. mSphere. 2021;6:e00052-21. doi: 10.1128/mSphere.00052-21.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mSphere.00052-21</ArticleId><ArticleId IdType="pmc">PMC8546680</ArticleId><ArticleId IdType="pubmed">33692193</ArticleId></ArticleIdList></Reference><Reference><Citation>Eckshtain-Levi M., Batty C.J., Lifshits L.M., McCammitt B., Moore K.M., Amouzougan E.A., Stiepel R.T., Duggan E., Ross T.M., Bachelder E.M., et al. Metal-Organic Coordination Polymer for Delivery of a Subunit Broadly Acting Influenza Vaccine. ACS Appl. Mater. Interfaces. 2022;14:28548–28558. doi: 10.1021/acsami.2c04671.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsami.2c04671</ArticleId><ArticleId IdType="pmc">PMC9495290</ArticleId><ArticleId IdType="pubmed">35704854</ArticleId></ArticleIdList></Reference><Reference><Citation>Skarlupka A.L., Zhang X., Blas-Machado U., Sumner S.F., Ross T.M. Multi-Influenza HA Subtype Protection of Ferrets Vaccinated with an N1 COBRA-Based Neuraminidase. Viruses. 2023;15:184. doi: 10.3390/v15010184.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v15010184</ArticleId><ArticleId IdType="pmc">PMC9865009</ArticleId><ArticleId IdType="pubmed">36680224</ArticleId></ArticleIdList></Reference><Reference><Citation>Criado M.F., Kassa A., Bertran K., Kwon J.H., e Silva M.S., Killmaster L., Ross T.M., Mebatsion T., Swayne D.E. Efficacy of multivalent recombinant herpesvirus of turkey vaccines against high pathogenicity avian influenza, infectious bursal disease, and Newcastle disease viruses. Vaccine. 2023;41:2893–2904. doi: 10.1016/j.vaccine.2023.03.055.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2023.03.055</ArticleId><ArticleId IdType="pubmed">37012117</ArticleId></ArticleIdList></Reference><Reference><Citation>Gandhapudi S.K., Shi H., Ward M.R., Bush J.P., Avdiushko M., Sundarapandiyan K., Wood L.V., Dorrani M., Fatima A., Dervan J., et al. Recombinant Protein Vaccines Formulated with Enantio-Specific Cationic Lipid R-DOTAP Induce Protective Cellular and Antibody-Mediated Immune Responses in Mice. Viruses. 2023;15:432. doi: 10.3390/v15020432.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v15020432</ArticleId><ArticleId IdType="pmc">PMC9965888</ArticleId><ArticleId IdType="pubmed">36851646</ArticleId></ArticleIdList></Reference><Reference><Citation>Carlock M.A., Ross T.M. A computationally optimized broadly reactive hemagglutinin vaccine elicits neutralizing antibodies against influenza B viruses from both lineages. Sci. Rep. 2023;13:15911. doi: 10.1038/s41598-023-43003-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-023-43003-2</ArticleId><ArticleId IdType="pmc">PMC10517972</ArticleId><ArticleId IdType="pubmed">37741893</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamlangdee A., Kingstad-Bakke B., Anderson T.K., Goldberg T.L., Osorio J.E. Broad protection against avian influenza virus by using a modified vaccinia Ankara virus expressing a mosaic hemagglutinin gene. J. Virol. 2014;88:13300–13309. doi: 10.1128/JVI.01532-14.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01532-14</ArticleId><ArticleId IdType="pmc">PMC4249068</ArticleId><ArticleId IdType="pubmed">25210173</ArticleId></ArticleIdList></Reference><Reference><Citation>Florek K.R., Kamlangdee A., Mutschler J.P., Kingstad-Bakke B., Schultz-Darken N., Broman K.W., Osorio J.E., Friedrich T.C. A modified vaccinia Ankara vaccine vector expressing a mosaic H5 hemagglutinin reduces viral shedding in rhesus macaques. PLoS ONE. 2017;12:e0181738. doi: 10.1371/journal.pone.0181738.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0181738</ArticleId><ArticleId IdType="pmc">PMC5542451</ArticleId><ArticleId IdType="pubmed">28771513</ArticleId></ArticleIdList></Reference><Reference><Citation>Corder B.N., Bullard B.L., DeBeauchamp J.L., Ilyushina N.A., Webby R.J., Weaver E.A. Influenza H1 Mosaic Hemagglutinin Vaccine Induces Broad Immunity and Protection in Mice. Vaccines. 2019;7:195. doi: 10.3390/vaccines7040195.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines7040195</ArticleId><ArticleId IdType="pmc">PMC6963302</ArticleId><ArticleId IdType="pubmed">31771231</ArticleId></ArticleIdList></Reference><Reference><Citation>Bullard B.L., Corder B.N., DeBeauchamp J., Rubrum A., Korber B., Webby R.J., Weaver E.A. Epigraph hemagglutinin vaccine induces broad cross-reactive immunity against swine H3 influenza virus. Nat. Commun. 2021;12:1203. doi: 10.1038/s41467-021-21508-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-21508-6</ArticleId><ArticleId IdType="pmc">PMC7900167</ArticleId><ArticleId IdType="pubmed">33619277</ArticleId></ArticleIdList></Reference><Reference><Citation>Bullard B.L., DeBeauchamp J., Pekarek M.J., Petro-Turnquist E., Vogel P., Webby R.J., Weaver E.A. An epitope-optimized human H3N2 influenza vaccine induces broadly protective immunity in mice and ferrets. NPJ Vaccines. 2022;7:65. doi: 10.1038/s41541-022-00492-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41541-022-00492-y</ArticleId><ArticleId IdType="pmc">PMC9226166</ArticleId><ArticleId IdType="pubmed">35739199</ArticleId></ArticleIdList></Reference><Reference><Citation>Petro-Turnquist E., Pekarek M., Jeanjaquet N., Wooledge C., Steffen D., Vu H., Weaver E.A. Adenoviral-vectored epigraph vaccine elicits robust, durable, and protective immunity against H3 influenza A virus in swine. Front. Immunol. 2023;14:1143451. doi: 10.3389/fimmu.2023.1143451.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2023.1143451</ArticleId><ArticleId IdType="pmc">PMC10225514</ArticleId><ArticleId IdType="pubmed">37256131</ArticleId></ArticleIdList></Reference><Reference><Citation>Petro-Turnquist E., Corder Kampfe B., Gadeken A., Pekarek M.J., Weaver E.A. Multivalent Epigraph Hemagglutinin Vaccine Protects against Influenza B Virus in Mice. Pathogens. 2024;13:97. doi: 10.3390/pathogens13020097.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pathogens13020097</ArticleId><ArticleId IdType="pmc">PMC10892733</ArticleId><ArticleId IdType="pubmed">38392835</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischer W., Perkins S., Theiler J., Bhattacharya T., Yusim K., Funkhouser R., Kuiken C., Haynes B., Letvin N.L., Walker B.D., et al. Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants. Nat. Med. 2007;13:100–106. doi: 10.1038/nm1461.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm1461</ArticleId><ArticleId IdType="pubmed">17187074</ArticleId></ArticleIdList></Reference><Reference><Citation>Barouch D.H., O’Brien K.L., Simmons N.L., King S.L., Abbink P., Maxfield L.F., Sun Y.H., La Porte A., Riggs A.M., Lynch D.M., et al. Mosaic HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeys. Nat. Med. 2010;16:319–323. doi: 10.1038/nm.2089.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.2089</ArticleId><ArticleId IdType="pmc">PMC2834868</ArticleId><ArticleId IdType="pubmed">20173752</ArticleId></ArticleIdList></Reference><Reference><Citation>Santra S., Liao H.X., Zhang R., Muldoon M., Watson S., Fischer W., Theiler J., Szinger J., Balachandran H., Buzby A., et al. Mosaic vaccines elicit CD8+ T lymphocyte responses that confer enhanced immune coverage of diverse HIV strains in monkeys. Nat. Med. 2010;16:324–328. doi: 10.1038/nm.2108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.2108</ArticleId><ArticleId IdType="pmc">PMC2834806</ArticleId><ArticleId IdType="pubmed">20173754</ArticleId></ArticleIdList></Reference><Reference><Citation>Theiler J., Yoon H., Yusim K., Picker L.J., Fruh K., Korber B. Epigraph: A Vaccine Design Tool Applied to an HIV Therapeutic Vaccine and a Pan-Filovirus Vaccine. Sci. Rep. 2016;6:33987. doi: 10.1038/srep33987.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep33987</ArticleId><ArticleId IdType="pmc">PMC5050445</ArticleId><ArticleId IdType="pubmed">27703185</ArticleId></ArticleIdList></Reference><Reference><Citation>Rahim M.N., Wee E.G., He S., Audet J., Tierney K., Moyo N., Hannoun Z., Crook A., Baines A., Korber B., et al. Complete protection of the BALB/c and C57BL/6J mice against Ebola and Marburg virus lethal challenges by pan-filovirus T-cell epigraph vaccine. PLoS Pathog. 2019;15:e1007564. doi: 10.1371/journal.ppat.1007564.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1007564</ArticleId><ArticleId IdType="pmc">PMC6394903</ArticleId><ArticleId IdType="pubmed">30817809</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenberg D.P., Robertson C.A., Noss M.J., Blatter M.M., Biedenbender R., Decker M.D. Safety and immunogenicity of a quadrivalent inactivated influenza vaccine compared to licensed trivalent inactivated influenza vaccines in adults. Vaccine. 2013;31:770–776. doi: 10.1016/j.vaccine.2012.11.074.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2012.11.074</ArticleId><ArticleId IdType="pubmed">23228813</ArticleId></ArticleIdList></Reference><Reference><Citation>Treanor J.T., Albano F.R., Sawlwin D.C., Graves Jones A., Airey J., Formica N., Matassa V., Leong J. Immunogenicity and safety of a quadrivalent inactivated influenza vaccine compared with two trivalent inactivated influenza vaccines containing alternate B strains in adults: A phase 3, randomized noninferiority study. Vaccine. 2017;35:1856–1864. doi: 10.1016/j.vaccine.2017.02.066.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2017.02.066</ArticleId><ArticleId IdType="pubmed">28302411</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaglani M., Vasudevan A., Raiyani C., Murthy K., Chen W., Reis M., Belongia E.A., McLean H.Q., Jackson M.L., Jackson L.A., et al. Effectiveness of Trivalent and Quadrivalent Inactivated Vaccines Against Influenza B in the United States, 2011–2012 to 2016–2017. Clin. Infect. Dis. 2021;72:1147–1157. doi: 10.1093/cid/ciaa102.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciaa102</ArticleId><ArticleId IdType="pmc">PMC8028105</ArticleId><ArticleId IdType="pubmed">32006430</ArticleId></ArticleIdList></Reference><Reference><Citation>Sautto G.A., Kirchenbaum G.A., Ecker J.W., Bebin-Blackwell A.G., Pierce S.R., Ross T.M. Elicitation of Broadly Protective Antibodies following Infection with Influenza Viruses Expressing H1N1 Computationally Optimized Broadly Reactive Hemagglutinin Antigens. Immunohorizons. 2018;2:226–237. doi: 10.4049/immunohorizons.1800044.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/immunohorizons.1800044</ArticleId><ArticleId IdType="pubmed">31022693</ArticleId></ArticleIdList></Reference><Reference><Citation>Kehagia E., Papakyriakopoulou P., Valsami G. Advances in intranasal vaccine delivery: A promising non-invasive route of immunization. Vaccine. 2023;41:3589–3603. doi: 10.1016/j.vaccine.2023.05.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2023.05.011</ArticleId><ArticleId IdType="pmc">PMC10173027</ArticleId><ArticleId IdType="pubmed">37179163</ArticleId></ArticleIdList></Reference><Reference><Citation>Krammer F. SARS-CoV-2 vaccines in development. Nature. 2020;586:516–527. doi: 10.1038/s41586-020-2798-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2798-3</ArticleId><ArticleId IdType="pubmed">32967006</ArticleId></ArticleIdList></Reference><Reference><Citation>Rando H.M., Lordan R., Kolla L., Sell E., Lee A.J., Wellhausen N., Naik A., Kamil J.P., Gitter A., Greene C.S. The Coming of Age of Nucleic Acid Vaccines during COVID-19. mSystems. 2023;8:e0092822. doi: 10.1128/msystems.00928-22.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/msystems.00928-22</ArticleId><ArticleId IdType="pmc">PMC10134841</ArticleId><ArticleId IdType="pubmed">36861992</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng S., Liang H., Chen P., Li Y., Li Z., Fan S., Wu K., Li X., Chen W., Qin Y., et al. Viral Vector Vaccine Development and Application during the COVID-19 Pandemic. Microorganisms. 2022;10:1450. doi: 10.3390/microorganisms10071450.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/microorganisms10071450</ArticleId><ArticleId IdType="pmc">PMC9317404</ArticleId><ArticleId IdType="pubmed">35889169</ArticleId></ArticleIdList></Reference><Reference><Citation>Kulkarni J.A., Witzigmann D., Thomson S.B., Chen S., Leavitt B.R., Cullis P.R., van der Meel R. The current landscape of nucleic acid therapeutics. Nat. Nanotechnol. 2021;16:630–643. doi: 10.1038/s41565-021-00898-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41565-021-00898-0</ArticleId><ArticleId IdType="pubmed">34059811</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>